Canex V

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Canex V

Quick Facts

Property Description
Active ingredient Clotrimazole (Clotrimazol)
Form Vaginal cream
Pharmacological class Azole antifungal (Antimycotic)
Common purpose Addresses localized fungal disturbances
Origin Synthetic drug (Imidazole derivative)

What Type of Medicine is Canex V? (Definition and Classification)

Canex V is a medicinal preparation whose core identity is defined by its active ingredient, Clotrimazole (Clotrimazol). This compound is classified as an Azole antifungal agent, a designation recognized globally, and is chemically specified as an Imidazole derivative. It functions as an Antimycotic, a type of therapeutic agent specifically developed to counteract the proliferation of fungal organisms. Its classification and efficacy against common yeasts are recognized for the management of superficial fungal issues.

Composition, Form, and General Purpose

The Canex V formulation is supplied as a Vaginal cream, a specific dosage form engineered for localized effectiveness via topical administration, distinguishing it from systemic oral treatments. This form dictates that the preparation's action is non-systemic, focusing the active substance at the precise area of concern. As a typically single-ingredient product, its function rests entirely on the Clotrimazole compound, which is suspended within a suitable cream base or vehicle to ensure proper delivery and adherence. This localized approach is central to its general purpose: to suppress fungal pathogens and thereby relieve the physical presence associated with localized mycoses.

Regulatory References

  1. Azole antifungal
  2. Antimycotic
  3. clinically recognized
  4. topical administration
  5. cream base or vehicle
  6. NIH Review
  7. MedlinePlus
  8. Active ingredient
  9. Vaginal cream
  10. dosage form

What side effects are possible with Canex V?

Possible Side Effects and Safety Information

The safety profile for Canex V (Clotrimazole vaginal cream) is established through official government regulatory documents and is predominantly characterized by effects at the application site. The medicine is primarily for localized use, and its side effects are categorized by frequency as defined in official prescribing information.

Documented Adverse Reactions

The most frequently reported adverse reactions are classified as Common, affecting up to 1 in 10 patients. These are localized effects under the Reproductive system and breast disorders and include pruritus (itching), burning sensations, and local discomfort at the site of application. Uncommon reactions may include pelvic or abdominal pain, as well as erythema (redness) and rash.

Serious Reactions and Safety Constraints

Regulatory documentation acknowledges the potential for rare, serious adverse reactions related to systemic hypersensitivity. These are classified under Immune system disorders and may include anaphylaxis, angioedema, syncope (fainting), and hypotension (low blood pressure).

An important safety constraint specified in official labeling concerns latex products. Laboratory data suggest that the cream formulation may compromise the integrity of latex barrier contraceptives, such as condoms and diaphragms, potentially reducing their reliability when used concurrently.

Population and Contraindications

The product is contraindicated in any individual with a documented hypersensitivity to the active substance Clotrimazole or to any of the specific excipients in the formulation. Official safety notes generally permit use during pregnancy and lactation, provided the medicine is used under professional supervision.

Overdose and Emergency Response

The official regulatory profile for clotrimazole vaginal cream classifies acute overdosage as unlikely to lead to a severe or life-threatening situation. This classification is based on the drug's limited systemic absorption, with only approximately 3% to 10% of the dose being absorbed following the intended vaginal route of administration.

Overdose risk is primarily constrained to the scenario of accidental oral ingestion of the cream. In such an event, the officially documented manifestations are primarily limited to systemic effects such as dizziness, nausea, and vomiting.

Required Emergency Actions

The most important instruction is to seek immediate medical attention if the cream is swallowed. Government regulatory guidance explicitly mandates that individuals must contact a local Poison Control Center (e.g., 1-800-222-1222) or local emergency services at once if the product is ingested or if the individual has collapsed.

Management and Monitoring

No specific antidote is known for clotrimazole. Therefore, management is limited to symptomatic and supportive treatment. If symptoms occur following oral ingestion, procedures such as gastric lavage should only be considered if clinical effects become apparent, and only when the airway can be protected adequately.

A note on co-administration: Official labeling states that patients taking oral immunosuppressants, such as tacrolimus or sirolimus, concomitantly with this vaginal cream should be monitored for signs of their overdosage.

Therapeutic Uses of Canex V

What Canex V Treats: Main Uses and Benefits

Canex V (Clotrimazole vaginal cream) is commonly used across therapeutic domains where short-term symptomatic assistance is needed to address localized fungal infections. Its application is relevant for easing symptoms linked to acute episodes of vulvovaginal candidiasis (VVC), commonly known as a vaginal yeast infection.

This medication is utilized as part of the symptomatic management for these types of infections. The therapeutic domain involves managing symptom clusters that may become noticeable or disruptive, such as pruritus (itching), burning sensations, redness, and soreness.

Quick Fact: Relief for Vulvovaginal Irritation

Focus Area Symptom Domain Practical Benefit
Primary Indication Vulvovaginal candidiasis (Yeast infection) Supports the patient by addressing acute symptomatic periods.
Symptom Cluster Itching, burning, soreness, and discharge. Contributes to easing the overall symptom load.
Clinical Context Symptoms that interfere with daily functioning. Assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Canex V? (Population Eligibility)

The official regulatory profile for Canex V (Clotrimazole vaginal cream) strictly defines eligibility based on a patient's age, clinical state, and medical history.

Populations That Must Not Use Canex V

Category Restriction Status
Hypersensitivity Known allergy to Clotrimazole or excipients Contraindicated
Symptom Profile Symptoms caused by non-fungal conditions Contraindicated
Complicated Symptoms Presence of fever, chills, abdominal pain, or abnormal bleeding/discharge Requires Medical Consultation

Age and Special Population Eligibility

Adults and adolescents mathbf12 years of age and over are the approved population for use. Use in children under 12 years of age is restricted and requires prior medical advice. Patients with a history of frequent or recurrent infections (more than twice in six months) or those with underlying conditions like Diabetes Mellitus or a weakened immune system must consult a healthcare professional before use.


Pregnancy and Lactation Status

Use during pregnancy is generally permitted, though consultation with a health professional is advised, especially during the first trimester. The medicine may be used during lactation as minimal systemic absorption makes effects on the nursing infant unlikely.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Clotrimazole vaginal cream addresses interactions that fall into two main categories: those affecting highly sensitive systemic medicines and those related to local product compatibility.

Pharmacokinetic and Exposure Interactions

Co-administration with specific oral immunosuppressants, such as Tacrolimus and Sirolimus, is documented to potentially increase the plasma levels of these systemic medicines. This pharmacokinetic interaction requires close monitoring, as noted in the regulatory labels, despite the low systemic absorption of the vaginal cream.

Local Product and Substance Restrictions

Interacting Substance Officially Documented Outcome
Latex Contraceptive Devices (Condoms, Diaphragms) Damage to the latex/rubber may occur, which results in reduced effectiveness of the device. Alternative precautions must be used during treatment and for a period after cessation.
Vaginal Spermicides Co-administration is documented to decrease the effectiveness of the spermicidal agent.
Other Topical Antifungals (e.g., Polyene Antibiotics) Clotrimazole may reduce the effect of other co-administered topical antifungal agents.

Food and Substance Notes

Regulatory sources state there are no known interactions between this vaginal formulation and food or drinks. The official regulatory profile does not list any formal contraindicated combinations with this formulation.

Mechanism of Action

Blocking the Pathway for Fungal Cell Components

Canex V acts as an inhibitor of the fungal enzyme C14 alpha-lanosterol demethylase, which is a key component of the cytochrome P450 family. This enzyme is necessary for the production of ergosterol, a primary sterol component of the fungal cell membrane. The result of this molecular interference is the alteration of the cell membrane's construction and stability.

Affecting Fungal Cellular Integrity

By preventing ergosterol synthesis, the drug's mechanism causes the fungal cell membrane to become structurally compromised and permeable. This disruption of the cell barrier initiates a sequence of changes, leading to the leakage of internal cellular contents. This process ultimately leads to fungal cell death as the final mechanistic event.

Dosage and Administration Information

The use of Canex V (clotrimazole vaginal cream) follows administration principles designed for intravaginal use. This delivery method serves to provide the active substance, clotrimazole, directly to the localized area of concern.

Administration Protocol

The standard regimens for the vaginal cream involve the daily use of a dedicated applicator to ensure the delivery of the specified dose, which is one full applicatorful (either the 1% or 2% strength). Administration is performed once daily. This application is typically scheduled at bedtime to maintain drug contact time and optimize retention within the vagina.

Duration and Constraints

Treatment follows a fixed course duration, generally defined as seven consecutive days for the 1% strength or three consecutive days for the 2% strength. The course is intended to be completed in its entirety, even if symptoms appear to subside earlier. Administration is generally avoided during the menstrual period to prevent medication washout. The use parameters are for adults and children 12 years of age and over.

External Application

A separate external cream component, often included in combination packs, may be applied topically to the vulvar and surrounding perivaginal areas up to twice daily, as an adjunct to the primary intravaginal regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Canex V (Clotrimazole Vaginal Cream)

The primary body of evidence for this medicine focuses on clinical evaluations, primarily from randomized trials and systematic reviews, which contributed to regulatory decisions regarding its approved indications. This overview summarizes what research has explored, what outcomes were monitored, and what aspects remain uncertain, based on official health authority documents and peer-reviewed scientific literature.

Evidence for Acute, Uncomplicated Vulvovaginal Candidiasis (VVC)

The evidence for this medicine focuses on acute, sporadic episodes of VVC, a condition characterized by episodic or acute changes in vulvovaginal symptoms. Studies conducted during periods of increased symptom activity have primarily used Randomized Controlled Trials (RCTs). These trials included Adult and Postmenarcheal Females and research examined specific patient-reported outcomes related to perceived discomfort and clinical signs.

Research has explored the association between treatment and measured Mycological Status (monitoring the presence of the Candida fungus) and patient-reported outcomes related to changes in symptoms (such as itching and burning). These studies often explored patterns between the cream and a placebo, and some studies included other localized antifungal treatments as comparators.

Research on Complicated and Recurrent Cases

Research has also been conducted for severe presentations or those recurrent conditions presenting with cycles of stability and flare-ups. For cases considered complicated, research examined prolonged or repeated topical regimens as they compare to standard acute treatment in terms of measured outcomes.

In studies focusing on recurrent VVC, research explored different treatment schedules and monitored the frequency of relapse over observation periods that were longer than those used for acute cases. Findings contribute to the broader evidence landscape by describing changes measured during the study period for these specific populations.

Evidence in Specific Populations

Most of the main randomized controlled trials have focused on adult women, and results apply only to the populations studied. However, research has been specifically conducted regarding the use of the cream in symptomatic pregnant women. Studies in symptomatic pregnant women are often referenced in official health guidelines when describing the evidence base for localized options for this population.

Limitations and Research Gaps

Research exploring short-term symptom changes often involves limited follow-up durations. The evidence base for acute cases is substantial but has recognized research limitation frames. For example, data for certain fungal species that are not C. albicans remain insufficient. Furthermore, long-term effects are not fully established, and research does not determine whether an individual will respond similarly to the group patterns observed in the trials.

Key Studies & References

  1. Clotrimazole Vaginal (Topical route) - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Canex V (FAQ)


Q: How long does it usually take for Canex V to start working?

A: Official documentation for the over-the-counter version advises that if symptoms do not start to improve within the first three days of the regimen, a healthcare professional should be consulted. If symptoms persist for more than seven days, medical advice is also recommended. This indicates that a noticeable change in symptoms is generally expected within the initial days of using the product.


Q: What are the most commonly reported side effects of Canex V?

A: According to official regulatory labeling, the most frequently reported side effects are localized reactions that occur at the application site. These include a burning sensation, pruritus (itching), and general local discomfort. These effects are generally classified as common occurrences.


Q: Does Canex V have an effect on birth control methods?

A: Official labeling advises caution regarding certain barrier methods of contraception. The cream formulation is documented to potentially damage latex contraceptive devices, such as condoms and diaphragms, which could reduce their effectiveness. The regulatory labeling does not specifically address interactions with hormonal birth control methods (like the pill or patch).


Q: What is the general success rate mentioned in the research for Canex V?

A: Official research evidence primarily focuses on evaluating clinical outcomes, such as measured changes in mycological status (fungus presence) and patient-reported symptom relief within the patient groups studied. Specific overall quantifiable success percentages are not generally published within the core drug labeling. Findings are presented to describe the ability of the medicine to address the condition it is approved to treat.


Q: What is the difference between side effects and an allergic reaction to Canex V?

A: Side effects are described as expected, common, and usually localized reactions, such as mild burning and irritation at the application site. In contrast, an allergic reaction (hypersensitivity) is classified as a rare, serious systemic event that may involve symptoms like severe swelling (angioedema), difficulty breathing, fainting (syncope), or a widespread rash.


Q: Why is it described that Canex V 'may' help, instead of 'will' help?

A: The use of cautious language like 'may' reflects the established medical understanding that individual patient response can vary. While studies demonstrate that the medicine is effective across a group of people, official sources cannot guarantee that every individual patient will achieve the same results observed in the trials.


Q: What if I'm using other topical products; can I still use Canex V?

A: Official information advises against using other intravaginal products, such as douches, spermicides, or tampons, during the course of treatment. The labeling also specifically documents that this medicine may reduce the effectiveness of other topical antifungal products if used at the same time.


Q: Does Canex V cause dryness or irritation?

A: Official documentation lists local adverse reactions including erythema (redness), rash, and burning sensations, which are all forms of local irritation. While the term 'dryness' is not explicitly listed, the commonly reported side effects cover the presence of local discomfort and irritation at the application site.


Q: Is Canex V the same kind of medicine as other similar products?

A: Canex V contains the active ingredient clotrimazole, which is classified as an azole antifungal agent. The medicine is one of several localized treatments used for this kind of condition. Other similar products may use the same active ingredient or a different active ingredient that belongs to the same pharmacological class.


Q: What should I do if I forget to use Canex V?

A: Official instructions describe the procedure for a missed dose, which involves applying the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed application should be skipped, and the regular schedule should be continued. The product should not be used in double amounts to make up for a missed dose.


Q: Can Canex V be used by people of all ages?

A: The medicine is officially approved for use by adults and adolescents who are 12 years of age and over. Use in children under 12 years old is restricted and requires prior consultation with a healthcare professional, according to official regulatory labeling.


Q: Are there any common over-the-counter medicines that interact with Canex V?

A: Official warnings primarily focus on interactions with specific prescription immunosuppressant medicines taken orally and with localized products like latex contraceptives. There are no documented pharmacokinetic interactions with common, non-immunosuppressant oral over-the-counter medicines listed in the core drug labeling.


Q: Is it normal to feel a mild burning sensation when using Canex V?

A: Official labeling documents a mild increase in vaginal burning, itching, or irritation as a possible and commonly reported side effect when using the product. While this sensation can be uncomfortable, it is described as being within the expected range of possible local reactions.


Q: Why do some people need to use Canex V more than once?

A: The treatment is primarily for acute episodes. However, official guidance notes that the treatment can be repeated if necessary. Regulatory information also specifies that recurrent infections (e.g., more than twice in six months) require professional medical consultation to identify any underlying factors.


Q: Does using Canex V prevent future problems?

A: Canex V is officially indicated to treat an existing vaginal yeast infection. The approved purpose of the product is therapeutic for the current episode, and its regulatory-approved use does not include a preventative claim for future infections.


Q: Can men use Canex V?

A: The primary intravaginal cream formulation is intended for the treatment of vulvovaginal candidiasis in females. However, the external cream component, often included in combination packs, can be applied topically for associated external symptoms in men, but specific use should be professionally guided.


Q: Is Canex V available without a prescription?

A: In many jurisdictions, clotrimazole vaginal cream is classified as an over-the-counter (OTC) medicine. This means it is typically available for purchase without a prescription for its approved uses.


Q: How long after using Canex V can I resume normal activities?

A: Official guidance recommends avoiding activities such as vaginal intercourse and the use of douches during the treatment period. Additionally, due to the risk of damaging latex, official sources suggest avoiding the use of latex contraceptives during the treatment and for a period afterward, with some sources recommending five days following the last dose.


Q: What should I do if I accidentally swallow some Canex V?

A: The product is strictly for vaginal use, and official labeling states it should be kept out of the reach of children. If the product is swallowed, official labeling indicates that professional medical attention or contact with a poison control center is advised immediately.


Q: Can I use Canex V with herbal supplements?

A: Authoritative regulatory sources generally state that there is insufficient information available regarding the interaction between clotrimazole and herbal remedies or supplements. It is recommended that a healthcare professional be consulted when considering co-administration with any herbal products.


Q: Why is Canex V sometimes prescribed for a longer time?

A: While the standard regimens for uncomplicated cases are typically 3 or 7 days, longer or repeated courses of topical treatment may be professionally advised. Official guidelines indicate that this may be considered for more severe or recurrent conditions, as supported by the research evidence overview.


Q: Does Canex V cause tiredness or fatigue?

A: The medicine is a localized treatment with low systemic absorption. Official adverse reaction listings in regulatory documents predominantly list localized effects at the application site, and tiredness or fatigue is not listed among the commonly or uncommonly reported adverse reactions.


Q: Is the sensation of relief immediate after using Canex V?

A: The drug's mechanism of action involves cellular changes that are not instantaneous. While relief may begin soon after application, official guidance suggests that symptom improvement should be monitored over the first three days of the regimen, not immediately after the first use.


Q: Are there any specific lifestyle changes recommended while using Canex V?

A: Regulatory documents recommend that during the course of treatment, patients should temporarily avoid the use of tampons, douches, and vaginal intercourse. These are considered temporary lifestyle adjustments related to the conditions of use.


Q: Are there certain times of day recommended for using Canex V?

A: Official directions advise that the application is typically performed once daily at bedtime. This recommendation is made to help optimize drug contact time and retention within the vagina.


Q: Can I be exposed to Canex V through close physical contact with someone using it?

A: Official warnings recommend avoiding vaginal intercourse during the use of the product. This recommendation is made in part to prevent potential transfer or exposure of the product to the partner, and to prevent damage to any latex products being used.


Q: Does Canex V affect blood pressure or blood sugar levels?

A: As a localized treatment with minimal systemic absorption, the medicine is not generally associated with changes in major systemic measures. Official adverse reaction listings do not include effects on blood pressure or blood sugar levels.


Q: Is the dose of Canex V the same for everyone?

A: The standard dose is one full applicatorful, which is consistent for all approved adults and adolescents 12 years of age and over, regardless of a person’s individual size or weight. The duration of treatment, however, varies based on the specific product strength used (3 or 7 days).


Q: What kind of misuses of Canex V are described in official warnings?

A: Warnings define constraints on use. Examples of misuse include not completing the full course of treatment, using the internal product during the menstrual period, or using douches, tampons, or spermicides concurrently. Additionally, engaging in vaginal intercourse during treatment is discouraged.


Q: What does the research say about the long-term use of Canex V?

A: The official research overview explicitly states that the evidence base for acute cases involves limited follow-up durations. Therefore, the core data reviewed for approval does not fully establish the long-term effects of the medicine.

How should Canex V be stored and disposed of?

Canex V (clotrimazole vaginal cream) must be stored strictly according to the conditions listed on the official regulatory label.

Official Storage and Handling

Requirement Regulatory Statement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep away from excessive heat and moisture, and do not freeze the product.
Container Keep the cream in its original container and ensure the tube is tightly closed.
Child Safety Store out of the sight and reach of children and pets.

Disposal Requirements

Unused or expired product should be discarded following official guidelines, such as using a drug take-back program (e.g., pharmacy collection site). If a take-back option is unavailable, the cream must be mixed with an undesirable substance (like dirt or coffee grounds), sealed in a bag, and thrown in the household trash. Do not flush the cream down the toilet or pour it down any drain, as directed by regulatory agencies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Canex V found in:

A-Z Index: